Acesso livre
Acesso livre

Arquivos do dia: Agosto 11, 2021

Estudo randomizado PRINCIPLE | Budesonida inalatória melhora o tempo de recuperação da COVID-19 em pessoas com alto risco de complicações na comunidade.

11 Ago, 2021 | 11:02h

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial – The Lancet

Comentário convidado: The use of inhaled corticosteroids in early-stage COVID-19

Diretriz OMS para vigilância das variantes do SARS-CoV-2.

11 Ago, 2021 | 11:00h

Guidance for surveillance of SARS-CoV-2 variants: Interim guidance, 9 August 2021 – World Health Organization

 

Comentário no Twitter (fio – clique para saber mais)

 

M-A | Infecção assintomática por SARS-CoV-2 – “Estima-se que a porcentagem de infecções que não levaram a sintomas clínicos, portanto, de fato assintomáticas, foi em torno de 35,1%.”

11 Ago, 2021 | 10:58h

Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis – Proceedings of the National Academy of Sciences

 

Comentário no Twitter

 

M-A | Mais de 50 efeitos de longo prazo da COVID-19.

11 Ago, 2021 | 10:57h

More than 50 long-term effects of COVID-19: a systematic review and meta-analysis – Scientific Reports

Conteúdos relacionados:

Illness duration and symptom profile in symptomatic school-aged children tested for SARS-CoV-2 – “Only 25 (1.8%) of 1379 children experienced symptoms for at least 56 days.”

Cohort study: Risk factors for long covid in previously hospitalized children.

Viewpoint: The road to addressing Long Covid.

Review: Long covid—mechanisms, risk factors, and management.

Review: Symptoms, complications and management of long COVID.

Long Covid: fatigue, post-exertional malaise, and cognitive dysfunction are the most common symptoms, according to an international survey.

Studies elucidate poorly understood long COVID.

Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents – “This study found a low prevalence of symptoms compatible with long COVID in a randomly selected cohort of children assessed 6 months after serologic testing”.

Long Covid: 39% of patients report persistent symptoms more than seven months after diagnosis of COVID-19 in an outpatient setting.

[Preprint] Long Covid: Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people.

Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms.

Long Covid: Half of young adults with COVID-19 have persistent symptoms 6 months after, study finds.

[Preprint] Long Covid: Third of people infected have long term symptoms.

Opinion | Causation or confounding: why controls are critical for characterizing long COVID – “Many of the self-reported symptoms, such as intermittent headaches or tiredness, are nonspecific and prevalent in the general population”.

Almost 25% of COVID-19 patients develop long-lasting symptoms, according to a new report.

Perspective | The four most urgent questions about long COVID.

Systematic review: Frequency, signs and symptoms, and criteria adopted for long COVID-19.

Report: 376,000 people in UK have had long Covid symptoms for at least a year.

Systematic review of 45 studies including 9751 participants, most of which were hospitalized, found 73% had at least 1 persistent symptom for weeks after Covid-19.

COVID Morbidity – The emerging burden of long COVID is significant, and needs to be considered when evaluating the risk vs. benefit of pandemic measures.

One year after hospital discharge due to SARS-CoV-2 Infection, the prevalence of long-term cough, chest pain, dyspnea, and fatigue was 2.5%, 6.5%, 23.3%, and 61.2%, respectively

Population-based cohort study: Non-hospitalized COVID-19 patients have low-risk of serious long-term effects, but visits to general practitioners and outpatient hospital visits are increased.

One third of patients hospitalized with COVID-19 have lung changes after a year

Long Covid: Largest post-acute COVID-19 study to date examined the health outcomes in more than 73,000 people who’d had COVID-19 and were not hospitalized

Study shows low incidence of post-acute COVID-19 symptoms (“Long Covid”) in children after mild disease

Perspective | They Tested Negative for Covid. Still, They Have Long Covid Symptoms.

Large study finds 1 in 3 Covid-19 survivors have subsequent mental health and neurological conditions

Cohort study: One in ten have long-term effects 8 months following mild COVID-19

Long Covid Implications for the workplace

Long Covid in the UK – More than a million affected in February, survey suggests

Covid-19: Middle aged women face greater risk of debilitating long term symptoms

Persistent neurologic symptoms and cognitive dysfunction in non‐hospitalized Covid‐19 “long haulers”

Opinion | We need to start thinking more critically — and speaking more cautiously — about long Covid

Review | Post-acute COVID-19 syndrome

Long Covid | Four-month clinical status of a cohort of patients after hospitalization for COVID-19

Perspective | Long Covid isn’t as unique as we thought

Attributes and predictors of long COVID

WHO Report: Preparing for Long COVID 2021

Long Covid: Sequelae in adults at 6 Months after COVID-19 infection

How many people get ‘long COVID’ – and who is most at risk?

Long Covid: Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge

Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline

Patients, clinicians seek answers to the mystery of ‘Long COVID’

Long Covid: 6-month consequences of COVID-19 in patients discharged from hospital

[Preprint] Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact

NICE Guideline: Managing the long-term effects of COVID-19

 

Comentário no Twitter

 

Relatório CDC | Morbidade e mortalidade da COVID-19 ultrapassaram muito os potenciais riscos de efeitos colaterais causados pelas vacinas.

11 Ago, 2021 | 10:54h

Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021 – CDC Morbidity and Mortality Weekly Report

Revisão | Características clínicas e tratamento farmacológico da trombocitopenia trombótica com trombose de seio venoso cerebral desencadeada por vacina contra COVID-19.

11 Ago, 2021 | 10:53h

Clinical Characteristics and Pharmacological Management of COVID-19 Vaccine–Induced Immune Thrombotic Thrombocytopenia With Cerebral Venous Sinus Thrombosis: A Review – JAMA Cardiology

Conteúdos relacionados:

NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (vários artigos e fontes sobre o tema)

 

Comentário no Twitter

 

Opinião | Não deveríamos descartar a possibilidade de erradicar a COVID-19: comparações com varíola e pólio.

11 Ago, 2021 | 10:49h

We should not dismiss the possibility of eradicating COVID-19: comparisons with smallpox and polio – BMJ Global Health

Comunicado de imprensa: Global eradication of COVID-19 probably feasible, and more so than for polio, say public health experts – British Medical Journal

Estudo randomizado BaSICS | Em pacientes criticamente doentes que necessitam de fluidoterapia, o tratamento com solução balanceada não reduziu a mortalidade em comparação com solução salina a 0,9%.

11 Ago, 2021 | 10:48h

Effect of Intravenous Fluid Treatment With a Balanced Solution vs 0.9% Saline Solution on Mortality in Critically Ill PatientsThe BaSICS Randomized Clinical Trial – JAMA (gratuito por tempo limitado)

Editorial: Does Crystalloid Composition or Rate of Fluid Administration Make a Difference When Resuscitating Patients in the ICU? – JAMA (gratuito por tempo limitado)

Vídeo: Balanced Solution vs. Saline in Intensive Care Study

 

Comentário no Twitter

 

Estudo randomizado BaSICS | Em pacientes criticamente doentes que necessitam de fluidoterapia, não houve diferença nas taxas de mortalidade com bolus de fluido intravenoso em infusão lenta (333 mL/h) vs. rápida (999 mL/h).

11 Ago, 2021 | 10:46h

Effect of Slower vs Faster Intravenous Fluid Bolus Rates on Mortality in Critically Ill Patients: The BaSICS Randomized Clinical Trial – JAMA (gratuito por tempo limitado)

Editorial: Does Crystalloid Composition or Rate of Fluid Administration Make a Difference When Resuscitating Patients in the ICU? – JAMA (gratuito por tempo limitado)

Vídeo: Balanced Solution vs. Saline in Intensive Care Study

Diretriz USPSTF recomenda o rastreamento do diabetes gestacional em grávidas assintomáticas com 24 semanas de gestação ou mais.

11 Ago, 2021 | 10:44h

Final Recommendation Statement: Gestational Diabetes: Screening – U.S. Preventive Services Task Force

Relatório da evidência: Screening for Gestational Diabetes: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force – JAMA

Editorial: Screening for Gestational Diabetes – JAMA

Entrevista com a autora: USPSTF Recommendation: Screening for Gestational Diabetes

Página do paciente JAMA: Screening for Gestational Diabetes

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.